The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Combined Accelerated Tissue-Plasminogen Activator and Platelet Glycoprotein IIb/IIIa Integrin Receptor Blockade With Integrilin in Acute Myocardial Infarction: Results of a Randomized, Placebo-Controlled, Dose-Ranging Trial
Abstract
Background Platelet activation and aggregation may be key components of thrombolytic failure to restore and maintain perfusion in acute myocardial infarction. We performed a placebo-controlled, dose-ranging trial of Integrilin, a potent inhibitor of platelet aggregation, with heparin, aspirin, and accelerated alteplase. Methods and Results We assigned 132 patients in a 2:1 ratio to receive a bolus and continuous infusion of one of six Integrilin doses or placebo. Another 48 patients were randomized in a 3:1, double-blind fashion to receive the highest Integrilin dose from the first phase or placebo. All patients received accelerated alteplase, aspirin, and intravenous heparin infusion; all but two groups also received an intravenous heparin bolus. The highest Integrilin dose group from the nonrandomized phase and the randomized patients were pooled for analysis and compared with placebo-treated patients. The primary end point was Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow at 90-minute angiography. Secondary end points were time to ST-segment recovery, an in-hospital composite (death, reinfarction, stroke, revascularization procedures, new heart failure, or pulmonary edema), and bleeding variables. The highest Integrilin dose groups had more complete reperfusion (TIMI grade 3 flow, 66% versus 39% for placebo-treated patients; P =.006) and a shorter median time to ST-segment recovery (65 versus 116 minutes for placebo; P =.05). The groups had similar rates of the composite end point (43% versus 42% for placebo-treated patients) and severe bleeding (4% versus 5%, respectively). Conclusions The incidence and speed of reperfusion can be enhanced when a potent inhibitor of the glycoprotein IIb/IIIa integrin receptor, such as Integrilin, is combined with accelerated alteplase, aspirin, and intravenous heparin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309023291001 · Cited by 4,055
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
Epstein, F. H., Fuster, V., Badimon, L., Badimon, J. J., & Chesebro, J. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201303260506 · Cited by 3,725
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
Epstein, F. H., Fuster, V., Badimon, L., Badimon, J. J., & Chesebro, J. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201233260406 · Cited by 2,717
The pathogenesis of coronary artery disease and the acute coronary syndromes (First of two parts)
Fuster, V. (1992) · New England Journal of Medicine · Cited by 1,954
(1993) · New England Journal of Medicine · doi:10.1056/nejm199311253292204 · Cited by 1,866
Platelet Activation in Unstable Coronary Disease
Fitzgerald, D. J., Roy, L., Catella, F., & FitzGerald, G. A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610163151602 · Cited by 1,141
Simes, R. J., Topol, E. J., Holmes, D. R., White, H. D., Rutsch, W. R., Vahanian, A. S., Simoons, M. L., Morris, D. C., Betriu, A., Califf, R. M., et al. (1995) · Circulation · doi:10.1161/01.cir.91.7.1923 · Cited by 484
Self-citationGold, H. K., Coller, B. S., Yasuda, T., Saito, T., Fallon, J. T., Guerrero, J. L., Leinbach, R. C., Ziskind, A. A., & Collen, D. (1988) · Circulation · doi:10.1161/01.cir.77.3.670 · Cited by 391
Scarborough, R. M., Naughton, M. A., Teng, W., Rose, J. W., Phillips, D. R., Nannizzi, L., Arfsten, A., Campbell, A. M., & Charo, I. F. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)54042-4 · Cited by 375
Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction?
Lincoff, A. M., & Topol, E. J. (1993) · Circulation · doi:10.1161/01.cir.88.3.1361 · Cited by 335
Self-citation
Cited by
WRITING COMMITTEE MEMBERS*, O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182742cf6 · Cited by 4,725
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
(1997) · New England Journal of Medicine · doi:10.1056/nejm199706053362301 · Cited by 948
Recognition of the Importance of Embolization in Atherosclerotic Vascular Disease
Topol, E. J., & Yadav, J. S. (2000) · Circulation · doi:10.1161/01.cir.101.5.570 · Cited by 770
Self-citationSnake venoms and the hemostatic system
Markland, F. S. (1998) · Toxicon · doi:10.1016/s0041-0101(98)00126-3 · Cited by 703
Metadata
- Authors
- Ohman, E. M., Kleiman, N. S., Gacioch, G., Worley, S. J., Navetta, F. I., Talley, J. D., Anderson, H. V., Ellis, S. G., Cohen, M. D., Spriggs, D., Miller, M., Kereiakes, D., Yakubov, S., Kitt, M. M., Sigmon, K. N., Califf, R. M., Krucoff, M. W., & Topol, E. J.
- Venue
- Circulation
- Published
- 1997-02-18
- Volume
- 95
- Issue
- 4
- Pages
- 846-854
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2094687142
- Cited by
- 378
- References
- 18
- FWCI
- 40.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combined Accelerated Tissue-Plasminogen Activator and Platelet Glycoprotein IIb/IIIa Integrin Receptor Blockade With Integrilin in Acute Myocardial Infarction: Results of a Randomized, Placebo-Controlled, Dose-Ranging Trial. https://app.cochat.ai/papers/10.1161/01.cir.95.4.846
- The paper
- Ohman, E. M., Kleiman, N. S., Gacioch, G., Worley, S. J., Navetta, F. I., Talley, J. D., Anderson, H. V., Ellis, S. G., Cohen, M. D., Spriggs, D., Miller, M., Kereiakes, D., Yakubov, S., Kitt, M. M., Sigmon, K. N., Califf, R. M., Krucoff, M. W., & Topol, E. J. (1997). Combined Accelerated Tissue-Plasminogen Activator and Platelet Glycoprotein IIb/IIIa Integrin Receptor Blockade With Integrilin in Acute Myocardial Infarction: Results of a Randomized, Placebo-Controlled, Dose-Ranging Trial. Circulation. https://doi.org/10.1161/01.cir.95.4.846
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.